A randomized phase I study of telisotuzumab adizutecan (ABBV-400, Temab-A) in combination with bevacizumab versus trifluridine-tipiracil with bevacizumab in patients with metastatic colorectal cancer.
M Cecchini, M Cruz-Correa, S-W Han, K Raghav, A Landa-Magdalena, J H Strickler, A Calvo, A Hollebecque, T E Nakajima, G Perl, V Jain, Z Hunter, E M Chan, M Blaney, R Li, A Vasilopoulos, A Parikh, M R Sharma
Ann Oncol S0923-7534(26)06887-0
摘要
摘要
BACKGROUND: Telisotuzumab adizutecan (ABBV-400, Temab-A) is an antibody-drug conjugate targeting c-Met (MET) protein with adizutecan, a novel topoisomerase 1 inhibitor payload. In monotherapy dose escalation, Temab-A demonstrated a manageable safety profile and promising antitumor activity in advanced colorectal cancer (CRC; NCT05029882). Based on these results, a randomized cohort of Temab-A + bevacizumab (Bev) versus trifluridine-tipiracil (FTD-TPI) + Bev (standard of care) was added with the hypothesis that addition of Bev would enhance efficacy. PATIENTS AND METHODS: Patients unselected for c-Met protein expression with advanced CRC were enrolled in two parts. In dose escalation, patients received Temab-A 1.6, 2.0, or 2.4 mg/kg + Bev 7.5 mg/kg every 3 weeks. In dose optimization, patients were randomly assigned to receive 1 : 1 : 1 Temab-A 2.0 or 2.4 mg/kg + Bev 7.5 mg/kg every 3 weeks, or FTD-TPI 35 mg/m2 days 1-5 and 8-12 every 4 weeks + Bev 5.0 mg/kg every 2 weeks. Primary objectives were safety, pharmacokinetics, and efficacy of Temab-A + Bev. RESULTS: Overall, 83 patients received treatment with Temab-A + Bev (n = 63) or FTD-TPI + Bev (n = 20) with median 3 (range, 1-8) prior lines of treatment and median follow-up of 18.2 months. Treatment-related adverse events were primarily gastrointestinal and hematological with low discontinuation rates [Temab-A 2.0: 3/26 (12%); Temab-A 2.4: 1/30 (3%)]. Objective response rate was 19% and 30% with Temab-A 2.0 and 2.4 + Bev, respectively, and 0% with FTD-TPI + Bev. For Temab-A 2.0 and 2.4 + Bev versus FTD-TPI + Bev, median progression-free survival was 5.6 and 6.8 versus 4.2 months; median overall survival was 11.2 (HR 0.75) and 14.7 (HR 0.62) versus 10.2 months, respectively. CONCLUSIONS: Temab-A 2.4 mg/kg + Bev demonstrated the most favorable risk-benefit profile, was tolerable, and had clinically meaningful improvements in efficacy versus FTD-TPI + Bev for advanced CRC. The regimen is being evaluated in the global randomized phase III trial AndroMETa-CRC-560 (NCT07525206).
KM 提取结果
0 个 Figure · 0 个 KM 面板